BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024
Rhea-AI Summary
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announces a KOL webinar scheduled for December 11, 2024, at 10:00 AM ET, focusing on Amyotrophic Lateral Sclerosis (ALS) treatment developments. The event will feature Dr. Terry Heiman-Patterson from Temple University's Lewis Katz School of Medicine, who will discuss the current ALS treatment landscape. BrainStorm's management will provide updates on their planned Phase 3b registrational clinical trial for NurOwn® (autologous MSC-NTF cells) and future development plans. The successful completion of Part A of the Phase 3b trial is expected to support a Biologic License Application (BLA) for NurOwn. The webinar will conclude with a live Q&A session.
Positive
- None.
Negative
- None.
News Market Reaction – BCLI
On the day this news was published, BCLI declined 1.72%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The webinar will feature Dr. Terry Heiman-Patterson, a KOL from the Lewis Katz School of Medicine at Temple University, who will discuss the current treatment landscape and advances for patients with amyotrophic lateral sclerosis (ALS). Dr. Heiman-Patterson will be joined by BrainStorm's management team, who will share updates on the company's planned Phase 3b registrational clinical trial, NurOwn® (autologous MSC-NTF cells), and future development plans.
Successful completion of the randomized portion (Part A) of the Phase 3b trial is expected to support a Biologic License Application (BLA) for NurOwn.
A live Q&A session will follow the formal presentations.
About Terry Heiman-Patterson, MD
Dr. Terry Heiman-Patterson is a pioneering figure in ALS care and research, with a career spanning decades of groundbreaking contributions to neurology. She is the Director of the Center for Neurodegenerative Disorders and a Professor in the Department of Neurology at the Lewis Katz School of Medicine at Temple University. Previously, she held esteemed roles as Vice Chair of the Department of Neurology, Director of the Division of Neuromuscular Disease, and Professor of Neurology at Drexel University College of Medicine in
For over 20 years, Dr. Heiman-Patterson directed the MDA/ALS Center of Hope at Drexel, and for more than 30 years, she led the outpatient Muscular Dystrophy Clinic at Good Shepherd Rehabilitation Center in
Dr. Terry Heiman-Patterson has spearheaded 24 clinical trials, establishing key standards in ALS care. She has authored more than 50 groundbreaking papers on motor neuron diseases and published hundreds of papers, abstracts, and book chapters on ALS and related disorders. Her work has earned national and international acclaim, including the prestigious Forbes Norris Award for her dedication to improving ALS patient care and advancing research
Dr. Heiman-Patterson earned her medical degree at Albany Medical College in
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the
Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the probability of NurOwn demonstrating a treatment effect in ALS, the patient enrollment and dosing in the Phase 3b trial for NurOwn®, and the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
IR:
Michael Wood
Phone: +1 646-597-6983
mwood@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original content:SOURCE BrainStorm Cell Therapeutics Inc.